RESEARCH ARTICLE

Novel Receptor-Derived Cyclopeptides to Treat Heart Failure Caused by Anti-β₁-Adrenoceptor Antibodies in a Human-Analogous Rat Model

Valérie Boivin¹,²,⁵*, Niklas Beyersdorf³, Dieter Palm², Viacheslav O. Nikolaev¹, Angela Schlipp¹,²,⁶, Justus Müller⁴, Doris Schmidt³, Vladimir Kocoski³, Thomas Kerkau³, Thomas Hünig³, Georg Ertl⁵, Martin J. Lohse¹,²,⁵, Roland Jahns¹,²,⁵

¹ Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany, ² Rudolf-Virchow-Center/DFG-Research-Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany, ³ Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany, ⁴ Institute of Pathology, University of Würzburg, Würzburg, Germany, ⁵ Comprehensive Heart Failure Centre (CHFC), University Hospital of Würzburg, Würzburg, Germany, ⁶ Lehrstuhl Anatomie I, University of München (LMU), München, Germany

* valerie.jahns@toxi.uni-wuerzburg.de

Abstract

Despite recent therapeutic advances the prognosis of heart failure remains poor. Recent research suggests that heart failure is a heterogeneous syndrome and that many patients have stimulating auto-antibodies directed against the second extracellular loop of the β₁-adrenergic receptor (β₁EC2). In a human-analogous rat model such antibodies cause myocyte damage and heart failure. Here we used this model to test a novel antibody-directed strategy aiming to prevent and/or treat antibody-induced cardiomyopathy. To generate heart failure, we immunised n = 76/114 rats with a fusion protein containing the human β₁EC2 (amino-acids 195–225) every 4 weeks; n = 38/114 rats were control-injected with 0.9% NaCl. Intravenous application of a novel cyclic peptide mimicking β₁EC2 (β₁EC2-CP, 1.0 mg/kg every 4 weeks) or administration of the β₁-blocker bisoprolol (15 mg/kg/day orally) was initiated either 6 weeks (cardiac function still normal, prevention-study, n = 24 (16 treated vs. 8 untreated)) or 8.5 months after the 1st immunisation (onset of cardiomyopathy, therapy-study, n = 52 (40 treated vs. 12 untreated)); n = 8/52 rats from the therapy-study received β₁EC2-CP/bisoprolol co-treatment. We found that β₁EC2-CP prevented and (alone or as add-on drug) treated antibody-induced cardiac damage in the rat, and that its efficacy was superior to mono-treatment with bisoprolol, a standard drug in heart failure. While bisoprolol mono-therapy was able to stop disease-progression, β₁EC2-CP mono-therapy -or as an add-on to bisoprolol- almost fully reversed antibody-induced cardiac damage. The cyclo-peptide acted both by scavenging free anti-β₁EC2-antibodies and by targeting β₁EC2-specific memory B-cells involved in antibody-production. Our model provides the basis for the clinical translation of a novel double-acting therapeutic strategy that scavenges harmful anti-β₁EC2-antibodies and also selectively depletes memory B-cells involved in the production of such antibodies. Treatment with immuno-modulating cyclopeptides alone or...
as an add-on to β₁-blockade represents a promising new therapeutic option in immune-mediated heart failure.

**Introduction**

Heart failure (HF) is a major cause of hospitalization and death; overall 50% of the patients die within four years of diagnosis [1]. HF may result from various causes and pathologies and is therefore considered a heterogeneous syndrome rather than a single disease entity. The presence of auto-antibodies directed against the β₁-adrenergic receptor (β₁-AR) apparently identifies a subgroup of patients at risk [2]. The β₁-AR mediates most of the cardiac effects of the catecholamines adrenaline and noradrenaline, which are often highly elevated and predict unfavorable prognosis in HF [3,4]. Whereas short-term β₁-AR stimulation improves cardiac performance, its chronic activation leads to progressive deterioration of cardiac structure and function [5].

During the past decade evidence has accumulated that many HF patients have functionally active autoantibodies directed against and stimulating the cardiac β₁-AR (anti-β₁-abs) [6,7,8]. Such anti-β₁-abs are found particularly in patients with idiopathic dilated cardiomyopathy (DCM), which is characterised by dilatation and impaired contraction of the left or both ventricles [9]. The presence of stimulating anti-β₁-abs is associated with reduced cardiac function [10], ventricular arrhythmias [2], sudden cardiac death [2,11], and increased cardiovascular mortality [2]. This suggests a potential for strategies to counteract such harmful receptor-antibodies.

Stimulating anti-β₁-abs almost exclusively target the second extracellular loop of the β₁-AR (β₁EC2), which is the largest and most structured of the three extracellular receptor loops and, thus, may represent a readily accessible target on the cell surface [12,13]. Moreover, β₁EC2 contains T- and B-cell epitopes [14,15]. Recent data derived from the receptor’s crystal structure underscore that β₁EC2 is essential for the stabilisation and locking of the receptor’s agonist binding pocket [13,16]. Thus, it seems conceivable that anti-β₁EC2 may allosterically induce an active state of the β₁-AR [12,17]. Immunisation of Lewis rats against the β₁EC2 gives rise to stimulating anti-β₁EC2, and within 8 months antibody-positive rats develop progressive cardiac dilatation, wall-thinning, and loss of contractile function typical for DCM [18]. Isogenic transfer of anti-β₁EC2 to naïve Lewis rats likewise induced HF in recipients [6,18].

To target such harmful antibodies, we conceived a novel peptide-based strategy aiming to specifically neutralise disease-inducing autoantibodies, in particular anti-β₁EC2. In this aim we generated peptide-homologs of β₁EC2 and cyclised them to increase their stability in vivo [19] and to better mimic the epitope-structure, and then investigated whether they might prevent or have a therapeutic effect (alone or -to better mimic the clinical situation- as add-on to β₁-blocker therapy) in our rat model of anti-β₁EC2-induced HF.

**Materials and Methods**

**Generation and characterisation of β₁EC2-cyclopeptides**

Linear peptides comprising 24 amino-acids of the human β₁EC2-sequence (AA199 to 222; ARAESDEARRCyNDPKCCFVTNRG) [20] were synthesised commercially on a Multiple Peptide Synthesizer (SYR0II, MultiSynTech GmbH, Witten, Germany) using the solid phase FMoc protocol with side chain protected FMoc amino-acid derivatives on Rink Amide MBHA resins (Novabiochem-Merck Biosciences GmbH, Bad Soden, Germany). For cyclisation of the
peptide on the solid phase, an additional Fmoc-Glu-ODmab was incorporated at the C-terminal end of the linear peptide; after selective removal of the Dmab side chain, the resin-bound linear peptide was treated with disopropyl-carbodiimide and N-hydroxy-9-azabenzotriazole in N,N′-dimethyl-formamide for several hours. The cyclisation process was monitored by repeated Kaiser’-tests [59]. Cleavage from the synthesis resin generated a peptide amide; the protective groups of the cyclopeptide were removed by treating the resin with trifluoro-acetic acid/triisopropylsilane/ethandithiole/water for 2 hours. The generated cyclopeptide β₁EC2-CP was analysed by high pressure liquid chromatography (HPLC), and by mass spectrometry (MALDI-MS).

A cyclic peptide corresponding to the β₂EC2-sequence (comprising AA182 to 204; RATHQEAINCYANETCCDFTNQG) [16] was synthesized and purified along the same lines and served as a control for specificity.

Study-protocol and generation and characterisation of anti-β₁-EC2-antibodies

Fusion-proteins (FP) between glutathion-S-transferase (GST) and the 2nd extracellular loop of the human β₁-AR (β₁EC2; AA195-225) [20] served as immunisation agent (β₁EC2/GST-FP). The study-protocol and guideline-conform animal housing conditions were approved by the local authorities (Vote No. 621-2531.01-35/04, Experimental Animal Use and Care Committee, Government of Lower Franconia, Bavaria, Germany).

In brief, n = 76 two months old Lewis/CrlBR rats were either s.c. immunised with 50 μg β₁EC2/GST-FP, or n = 38 rats were control-injected with 0.9% NaCl (t = 0). To maintain high anti-β₁EC2-titers, all immunised rats were boosted with β₁EC2/GST-FP (or 0.9% NaCl) every month over 20 months as previously described [18]. Application of the different linear or cyclic β₁-AR peptides (corresponding to the primary AA-sequence of either the first (β₁EC1) or the 2nd extra-cellular β₁-AR loop (β₁EC2)) or the β₁-receptor blocker bisoprolol was initiated either 6 weeks after the 1st immunisation (i.e. 15 days after the 1st boost, prevention-study), or 8.5 months after the 1st immunisation (therapy-study). At 4-week-intervals the animals received either preventive (n = 24, treatment arms a, b, and f only) or therapeutic (n = 52, treatment arms a-f) interventions over 12 months with (a) β₁EC2-CP (1.0 mg/kg intravenously (i.v.)), (b) bisoprolol (15 mg/kg/day orally, derived from titration pre-experiments [5/10/15mg] as oral dose decreasing heart rate by at least 10%, e.g., 15mg: from 236±10 to 205±9 bpm; n = 5, p<0.005), (c) β₁EC2-Lin (1.0 mg/kg i.v.), (d) β₁EC1-Lin (1.0 mg/kg i.v.), (e) β₁EC2-CP (1.0 mg/kg i.v.) plus bisoprolol (15 mg/kg/day orally) co-treatment, or (f) no specific treatment (immunised “positive” controls).

For treatment groups (a), (b), and (f) in total n = 38 non-immunised rats were injected with 0.9% NaCl and treated in parallel (“negative” controls). Blood was taken at regular intervals; rat-IgG was prepared by caprylic acid precipitation and assayed for reactivity by ELISA or competition-ELISA against linear peptides corresponding to the human β₁EC2-sequence (AA199-223) [12], and by immuno-fluorescence microscopy with human embryonic kidney (HEK)293 cells stably expressing 0.4 pmol β₁-AR/mg membrane protein (HEKβ₁-cells) [18]. Specificity of the anti-β₁EC2-abs was confirmed by co-localisation experiments using previously characterised N-terminal rabbit anti-β₁-abs [21]. Bound antibodies were detected with appropriate species-specific secondary antibodies (Dianova, Hamburg, Germany; anti-rabbit-, or anti-rat-Fab₂, conjugated to Cy2 or Cy3). Calibrated rat-IgG (Dianova) served to quantify specific IgG-antibodies.

The effects of anti-β₁EC2 on β₁-AR-mediated intracellular cAMP-production were assessed by measuring fluorescence resonance energy transfer (FRET) in HEKβ₁-cells transiently
transfected with a FRET-sensor for cAMP, Epac1-camps [8]. The sensor consists of the cAMP-binding protein Epac1 flanked by enhanced cyan or yellow fluorescent protein. 48 h after transfection with Epac1-camps, cAMP measurements were performed microscopically as described [8]. The cells were maintained in FRET-buffer supplemented with 50 nM ICI 118551 (Sigma, Deisenhofen, Germany) to block the small level of endogenous β2-AR (∼0.1 pmol/mg membrane protein). IgG-preparations were added to the cells at 0.13 μg/μl protein concentration; 2μM (-)isoproterenol (Sigma) was used as a reference to determine the maximal cAMP-response. To test the blocking-efficacy of β1EC2-CP on anti-β1EC2-induced adrenergic signaling, the different IgG-preparations were pre-incubated with β1EC2-CP (20 μg/μl) for 6 h at 4°C; for pharmacological blockade of anti-β1EC2-induced signals we utilised 5.0 μM bisoprolol.

Echocardiography and haemodynamic measurements

Echocardiograms were obtained from lightly anaesthetised rats (30 mg/kg ketamine-HCl and 5 mg/kg xylazine i.p.) with a Vevo770 system (Visual Sonics Inc., Toronto, Canada) equipped with a 17.5 MHz transducer as previously described [18], always by the same experienced echocardiographer, who was blinded to the treatment groups. In brief, the rats were lightly anaesthetised (30 mg/kg ketamine-HCl and 5 mg/kg xylazine i.p.), shaved (chest), and placed supine on a special table. M-mode tracings were recorded at baseline (before immunisation), and subsequently every four months in the parasternal long and short axis views according to the guidelines of the American Society for Echocardiography [22]. Pulsed-wave Doppler spectra were recorded from the apical five-chamber view and the velocity-time integral (VTI) of the transaortic flow served to calculate cardiac output (CO [ml/min] = Aortic VTI x (π [LV-outflow tract diameter/2]²) x bpm). Reproducibility of the echocardiographic measurements was assessed as previously described [18]; intra- and interobserver variabilities were <2% or <5%.

Forty-eight to 72 h after the final echo-Doppler examinations the rats underwent left heart catheterisation using a 3.5 F high-fidelity catheter (Millar Instruments, Houston, Texas) as described in [18]. LV-pressure tracings were recorded digitally over 15 min and analysed off-line (PowerLab, A.D. Instruments, Castle Hill, Australia) [18].

Macronatomy and histology of rat tissues

After further deep anesthesia (70 mg/kg sodium pentobarbital i.p.), the hearts were quickly removed, rinsed with ice-cold relaxing-buffer (5% dextrose, 25 mM KCl in PBS), and weighed. The apex was cut, frozen in isopentane (-56°C), and stored at -80°C for further analysis (binding and gene expression studies); the remainig tissue was fixed in 10% PBS-buffered formalin (24–28 h). After the hearts all other relevant inner organs (e.g., lung, liver, spleen, kidneys, brain, and eyes) were removed, rinsed with ice-cold PBS, weighed, sectioned, and fixed for further histologic analysis.

Heart morphometry, histology, and TUNEL assay

From paraffin-embedded heart preparations cavity- and wall-dimensions were determined by computer-aided analysis of H&E-stained mid-ventricular 2μm-sections as previously described [18]. H&E-stained paraffin-sections also served to quantify damaged and fibrotic cardiac areas (scars). For detection of mast cells, deparaffinised cardiac sections were stained with acidified (pH<2.5) toluidine blue 0.1% (Sigma). The number of toluidine-positive cells was normalized to square millimeter of cardiac tissue. TUNEL-positive cells were quantified in 2μm mid-ventricular paraffin-sections using a TMR Red in Situ Death Detection Kit (Roche, Basel, Switzerland). Only the total number of TUNEL-positive cells/section was determined without
further differentiation of the specific apoptotic cell type (e.g., fibroblasts, endothelial cells, cardiomyocytes).

**Membrane preparation and radioligand binding studies**

Membranes from apical cardiac tissues from rats of each study-group were prepared as previously described [18]. To determine total β-AR density (B$_{max}$), 35μg membrane protein were incubated (1.5 h, 25°C) in binding buffer with 200pM of the non-selective β-AR antagonist $^{125}$I-cyanopindolol ($^{125}$I-CYP; Perkin Elmer Life and Analytical Sciences, Billerica, MA). Non-specific binding was determined with 5μM unlabeled L-propranolol. The proportion of β$_1$- and β$_2$-AR subtypes was estimated from biphasic competition-curves with 10$^{-10}$ to 10$^{-2}$ M of the unlabeled β$_1$-selective antagonist CGP20712A (Sigma). The reaction was stopped by rapid filtration (Whatman GF/C filters) and washing with ice-cold buffer. Filter-bound radioactivity was measured by γ-counting. Estimates of maximal binding (B$_{max}$) and the proportion of β$_1$- and β$_2$-AR-subtypes were calculated with GraphPad Prism 5.00 (San Diego, CA).

**Cardiac gene expression**

Total RNA was isolated from frozen myocardium by RNeasy mini Kit (Qiagen, Hilden, Germany). Reverse transcription of total RNA isolated from frozen myocardium was performed in 96-well plates utilising a high capacity RNA-to-cDNA master mix (Applied Biosystems, Foster City, CA). PCR reactions were conducted in the presence of the fluorescent dye Sybr-Green (Cambrex BioScience, East Rutherford, NY) and the reference-dye 6-carboxy-X-rhodamine (ROX) using an ABI PRISM sequence detection system 7700 (Applied Biosystems). All amplification products were controlled for specificity by running a melting curve analysis; results were calculated using the 2$^{-ΔΔCT}$ method. The relative expression levels were derived from a standard curve and normalised to GAPDH as an endogenous control. Quantitative real-time PCR (qRT-PCR) analyses are presented as fold change compared to untreated (0.9% NaCl-injected) control hearts.

The primer-sequences were as follows (5’−3’): β$_1$-AR sense: ATGGGTGTGTT-CACGCTCTG, anti-sense: CAGCCAGTTGAAGAAGACGA; GRK2 sense: AGAGGGATGT-CAATCGGAGA, anti-sense: AAGACCATCTGCCAGTCCAG; GRK5 sense: ACCCTCCCTTCGTTCAG, anti-sense: ACTTTGACCATACCGACAT; IL1-β sense: AAATGCCTCGTGCTGTCTG, anti-sense: TCGTTGCTTGTCTCTCTTG; TGF-β1 sense AAGAAGTCACCGCCTGCTA, anti-sense: TGTGTGATGTCTTTGGTTTG.

**Detection of antigen-specific CD4$^+$ T-cells and memory B-cells as well as antibody-secreting plasma cells, and plasmablasts**

(a) **Recall-assays with T-cells** from spleens of immunised untreated vs. β$_1$EC2-CP-treated animals were conducted as described in [60]. In brief, to purify CD4$^+$ T-cells from the splenic cell preparations, B-cells and CD8$^+$ T-cells were depleted by commercially available magnetic beads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany) yielding a purity >85%. 1x10$^5$ of the purified CD4$^+$ T-cells were then co-incubated in 96-well plates with 1x10$^6$ irradiated thymic antigen presenting cells (prepared from a younger rat). Reagents added in the different assays were 1.0 μg/ml β$_1$EC2-CP, 1.0 μg/ml tuberculin purified protein derivative (PPD, internal control), 1.0 μg/ml glutathion-S-transferase (GST), as well as 1.0 and 0.1 μg/ml GST/β$_1$EC2-fusion proteins (FP), respectively. Measured T-cell reactivities were normalised to medium. After 48 h of incubation the cells were pulsed with 1.25 μCi/well $[^3]$H]-thymidine and further incubated for 16 h before the cells were harvested; the DNA-incorporated radioactivity was measured using a beta-plate counter.
(b) For ELISPOT assays plates were coated overnight with either 1.8 μg/ml anti-rat IgG (H-L) or the specific antigens (GST/β1EC2-FP or GST alone) in 50 mM Tris-buffer, pH 9.4. The plates were then washed 3 times, blocked with BSA (3h, 37°C), and incubated overnight at 37°C with splenocytes or bone marrow cells from rats treated as indicated in RPMI 1640/X-VIVO-15 medium supplemented with 10% FCS (1x10⁵ to 10⁶ cells per well). After 12 h the cells were discarded and the plates were washed several times (PBS/0.5% Tween) before an alkaline phosphatase-conjugated secondary anti-rat-IgG antibody (0.3 μg/ml) was added to detect bound rat IgG. After further incubation (3h, 37°C) and washing-steps (3 times PBS/0.5% Tween) the plates were developed using LMP/BCIP 5:1 (1.0 ml per well; LMP, low melting agarose; BCIP, 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt, a blue-colored dye).

(c) For flow cytometric detection of β1EC2-specific memory B-cells, splenocytes (1.5x10⁸ cells per staining, 2x10⁷ cells/ml in PBS/0.1% BSA/0.02% NaN₃) were first labelled with anti-rat IgG(Fc) PE (Jackson Immunoresearch, West Grove, USA) followed by three washings and a blocking step using normal rat serum plus GST (1:500 and 2 μg/ml, respectively). After another washing step, OX-33 FITC (BD, Heidelberg, Germany, 0.1 μg/ml) and DyLight649-labelled GST/β1EC2-FP (0.2 μg/ml) were added. All incubations were carried out for 15 min on ice and in the dark. Finally, the cells were washed three times and analysed on a FACS-Calibur (BD, Heidelberg, Germany) and FlowJo Software (Tree Star, Ashland, USA) was used to analyse the data.

(d) To detect functional β1EC2-specific memory B-cells in vivo, B-cells were first purified from total splenocytes by negative depletion using mAb V65, R73, 10/78 and WT.5 plus magnetic beads (MACS, Miltenyi Biotec, Bergisch-Gladbach, Germany) yielding average purities of 87%. 2.6x10⁷ purified B cells were injected in 250 μl PBS i.v. into antigen-naïve syngeneic male Lewis rats. To selectively trigger the transferred memory B-cells, recipient rats were immunised after five days with only 12.5 μg GST/β1EC2-FP in adjuvans per animal. Serum was collected for antibody detection just before as well as three and seven days after immunisation. Rats without (memory) B-cell transfer did not produce anti-β1EC2 IgG within the seven-day observation period (data not shown).

Statistical analyses
Data are given as mean ±SEM of at least four animals per treatment-group if not otherwise stated. Statistical analyses were performed using GraphPad Prism 5.00 (San Diego, CA). Functional assays (FRET), molecular parameters (qRT-PCR), as well as haemodynamic and morphometric parameters of antibody-positive vs. corresponding control rats or untreated vs. treated animals, respectively, were analysed by Student’s t-test (where applicable) or repeated measurements one-way ANOVA; significance between the different groups was analysed by Dunnett’s post-test.

Kinetics of anti-β1EC2-antibodies and/or the different peptides (where applicable) and differences between functional and echocardiographic parameters (long-term follow-up) were analysed by two-way ANOVA followed by Bonferroni post-hoc testing. Values of p<0.05 were considered statistically significant.

Results
Generation and neutralisation of stimulating anti-β1EC2-antibodies
To generate the anti-β1EC2-induced HF model, we immunised 68 male Lewis/CrlBR rats with fusion-proteins (FP) containing glutathion-S-transferase (GST) and the human β1EC2 (amino-acids AA195-225)[20] every month in accordance with institutional guidelines as described before [18]. All immunised rats developed high anti-β1EC2-titers (IgG-subclass, for all
experiments prepared by caprylic acid precipitation), peaking 5–6 months after the 1st immunisation.

Specificity and conformational character of the resultant anti-\(\beta_1\)EC2 towards \(\beta_1\)-ARs was ascertained along several lines: by larger ELISA signals with cyclic vs. linear \(\beta_1\)EC2-peptides (Fig. 1A), by a better recognition of cyclic vs. linear \(\beta_1\)EC2-peptides in blocking assays (together with a clear preference for \(\beta_1\) over \(\beta_2\)-EC2 sequence (Fig. 1B)), and by a better concentration-dependent neutralization in vitro achieved with cyclic vs. linear \(\beta_1\)EC2-peptides (Fig. 1C). In addition, immunofluorescence-studies confirmed that all rat anti-\(\beta_1\)EC2 stained native human \(\beta_1\)-AR in the membrane of stably transfected human embryonic kidney cells (HEK\(\beta_1\)-cells), and co-localised with purified \(\beta_1\)-specific amino-terminal rabbit antibodies [21] (Fig. 1D). Finally, the anti-\(\beta_1\)EC2 stimulated \(\beta_1\)-AR-mediated signaling in HEK\(\beta_1\)-cells, as evidenced by an increase in cAMP monitored with a co-transfected sensor that shows a decrease in fluorescence resonance energy transfer (FRET) upon binding of cAMP [8]; these signals varied in amplitude and in some cases almost reached the effects induced by the \(\beta\)-AR agonist isoproterenol (Fig. 1E, right panel). No such cAMP-signals were detected with IgG prepared from 0.9% NaCl-injected control rats (Fig. 1E, left panel). Also, control IgG reacted neither with \(\beta_1\)EC2-peptides in ELISA or competition assays (not shown), nor with \(\beta_1\)-AR expressed in HEK-cells (Fig. 1D). Stimulation of \(\beta_1\)-AR/ cAMP signaling by anti-\(\beta_1\)EC2 was inhibited by pre-incubation with \(\beta_1\)EC2-peptides, again better by cyclic than by linear peptides (Fig. 1F, top panels); interestingly, this inhibition was more efficient than that achieved by the specific \(\beta_1\)-AR antagonist bisoprolol (Fig. 1F, bottom right). As internal controls, we also generated cyclic EC2-peptides of the \(\beta_2\)-AR (\(\beta_2\)EC2-CP). In ELISA, competition- and FRET-assays, anti-\(\beta_1\)EC2 was not blocked at all by these \(\beta_2\)-AR-derived peptides, documenting the \(\beta_1\)-AR-specificity of the generated antibodies (Fig. 1B and Fig. 1F, bottom left).

Cyclisation of the \(\beta_1\)EC2-peptides not only improved recognition by the anti-\(\beta_1\)EC2-antibodies but, as predicted from studies on cyclotides from Viola odorata [19], also helped to increase their stability in the circulation. Because plasma-half life in vivo as determined by \(^{123}\text{I-\text{tyrosine}}\)-labeled \(\beta_1\)EC2 linear (t\(_{1/2}\) = 3.9±2.2 min) or cyclic \(\beta_1\)EC2-peptides (t\(_{1/2}\) = 8.1±2.8 min; n.s.) in central venous blood samples (gamma-counted 2, 4, 6, 8, 10, 20, 30, and 60 min after injection of 1.4 to 1.8 MBq \(^{123}\text{I-labeled peptide/animal, not shown}\)) merely reflected a comparable instantaneous distribution of the respective radiolabeled peptides in the circulation—not considering, e.g., extra-vascular accumulation and/or capillary redistribution (!)—we performed additional ex vivo incubation experiments with whole blood to analyse differences in peptide-stability strictly dependent on cyclisation. The latter experiments showed a significantly longer half-life of \(\beta_1\)EC2-CP (days) than that of its linear counterpart, \(\beta_1\)EC2-Lin (hours), inferring that cyclopeptides are more resistant to degradation by serum-peptidases than linear peptides (Fig. 1G). Taken together, these data suggested that based on its specificity and longer half-life in blood, the cyclopeptide \(\beta_1\)EC2-CP might represent a promising drug candidate for our immunisation-induced HF-model.

\(\beta_1\)EC2-cyclopeptides prevent and reverse anti-\(\beta_1\)EC2-induced heart failure

The protocols of the two studies to either prevent or treat anti-\(\beta_1\)EC2-induced HF are shown in Fig. 2A and E. The rats were either immunised with \(\beta_1\)EC2/GST-FP (n = 76) or control-injected with 0.9%NaCl (n = 38), and boosted every month in order to maintain high anti-\(\beta_1\)EC2-titers. Application of the different peptides or bisoprolol was initiated either 6 weeks after the 1st immunisation (i.e., 15 days after the 1st boost), when cardiac function was still fully normal (called prevention-study, Fig. 2A), or 8.5 months after the 1st immunisation, at the
Fig 1. Characterisation of stimulating rat anti-β1EC2. (A) ELISA-reactivity (mean±SEM) of n = 6 representative rat anti-β1EC2 (1:5000, 12h, 4°C) with linear (dark green) or cyclic β1EC2-peptides (light green); p<0.005 (Student’s t-test). (B) Blocking capacity of linear β1EC2- or cyclic β1- and β2EC2 peptide-homologues determined by competition-ELISA with linear β1EC2-peptides as antigen (AA199-223); columns are mean titers ±SEM. remaining in the sera after preincubation (12h, 4°C) with a 40-fold excess of β1- or β2EC2-CP, or β2EC2-Lin (n = 20; **p<0.001, one way ANOVA and Dunnett’s post-hoc test). (C) ELISA-competition experiments demonstrating the concentration-dependent blockade of rat anti-β1EC2 after preincubation with increasing amounts of linear (squares) or cyclic β1EC2-peptides (diamonds); error bars indicate mean ±SEM of n = 3; *p<0.01; **p<0.001 (two way ANOVA and Bonferroni post-hoc test). (D) Immunostaining experiments with rat anti-β1EC2 (1:100) using HEK-cells stably expressing β1-ARs (HEK β1) or not (wild type; HEK WT). IgG was prepared from anti-β1EC2-positive rats or 0.9% NaCl-injected control rats. Amino-terminal β1AR-specific rabbit antibodies (1:250) served as positive controls [21]. (E) Changes in cAMP levels in HEK β1-cells by rat anti-β1EC2. HEK β1-cells were transfected with the cAMP-sensor Epac1-camps [8], which reacts to cAMP-binding with a reduction in fluorescence resonance energy transfer (FRET) between its fluorophores cyan (CFP) and yellow fluorescent protein (YFP). Anti-β1EC2-induced activation of β1-AR causes increases in cytoplasmatic cAMP, resulting in a decrease in FRET. Representative FRET-ratio traces of 1/8 experiments with rat anti-β1EC2 and control IgG are shown. (F) Blockade of anti-β1EC2-induced cAMP-signals after pre-incubation with β1EC2-CP, β1EC2-Lin, β1EC2-CP (12h, 4°C) or 5.0 μM bisoprolol. Representative FRET-ratio traces of 1/5 experiments are shown. Values are given in % of maximal cAMP-response achieved with 0.3μM (-)isoproterenol (Iso). (G) Half-life of β1EC2-peptides in rat whole blood at room temperature. Rabbit anti-β1EC2 served to determine the amount of intact peptides remaining after 2, 10, 30 min, 1, 2, 4, 8, 17, and 22 h by competition-ELISA with linear β1EC2-peptides as antigen (duplicate experiments). Half-lifes derived from exponential curve fits were: β1EC2-CP, 486 h; β1EC2-Lin, 4 h.

doi:10.1371/journal.pone.0117589.g001
Fig 2. Study protocol and cardioprotection with cyclic β1EC2-peptides. Flow charts of the (A) prevention- and (E) therapy-study with β1EC2-mimicking peptides in the rat. Numbers given refer to animal-numbers in the respective study-groups. Immunisation with β1EC2/GST-FP (or 0.9% NaCl for controls) was started at t = 0. Six weeks or 8.5 months after the 1st immunisation with β1EC2/GST-FP and onset of cardiomyopathy the rats received preventive or therapeutic interventions with the indicated substances every 4 weeks over one year. Immunised untreated animals served as positive, 0.9% NaCl-injected controls.
rats as negative controls. Time-course of anti-β1EC2-titers in the (B) prevention- and (F) therapy-study. Titers were measured before and 24h after CP-injection. Values in (B) correspond to the anti-β1EC2-titers in mg/ml over 16 study-months (black circles, untreated; diamonds, β1EC2–CP (1.0 mg/kg/month i.v.); triangles, bisoprolol (15 mg/kg/day orally)). Values in (F) correspond to the anti-β1EC2-titers in mg/ml over 20 study-months (black circles, untreated; green diamonds, β1EC2-CP mono-treated; blue triangles, bisoprolol mono-treated; purple diamonds, β1EC2-CP/bisoprolol co-treated). For better readability error-bars are not shown in the graph. Echocardiography in the (C) prevention- and (G) therapy-study. Graphs show the time-course of the LV end-diastolic diameter (LVED). Lower panels: Time-course of the cardiac index derived from cardiac output/body weight. Error bars indicate mean ±SEM of the indicated groups; ns, not significant; *p<0.01; **p<0.001 (two way ANOVA and Bonferroni post-hoc test). Invasively obtained parameters in the (D) prevention- and (H) therapy-study. Upper panels show LV end-diastolic pressures (mmHg), lower panels contractilility (+dP/dt, mmHg/s). Error bars indicate mean ±SEM of the indicated groups; ns, not significant; *p<0.01; **p<0.001 (one way ANOVA and Dunnett’s post-hoc test).

doi:10.1371/journal.pone.0117589.g002

In contrast, monthly preventive application of β1EC2-CPs from their very first injection on abolished a further increase in anti-β1EC2-titers, and after 5 injections induced a >80% reduction in free anti-β1EC2-CP (vs. initial values, Fig. 2B). After 9–10 β1EC2-CP-injections, anti-β1EC2-titers had decreased to barely 10% of the initial values despite monthly antigen-boosts (Fig. 2B). In the therapy-study, the scavenger effect of β1EC2-CP was similar, yielding a progressive decline in anti-β1EC2-titers by >70% after two, and by >90% after 4–5 injections (Fig. 2F), irrespective of bisoprolol co-treatment. After each injection, the acute scavenging-effect was visible; in addition, there was a sustained anti-β1EC2-decline despite monthly antigen-boosts which resulted in steady state antibody-levels less than 15% of the titers at initiation of therapy. In contrast, therapy with β1EC2-Lin produced only negligible effects, and injection of β1EC2-Lin (S1 Fig.) or oral mono-treatment with bisoprolol (Fig. 2F, and S2B and S2F Fig.) had no effect on anti-β1EC2-titers at all.

In both studies cardiac function was followed every 4 months by echocardiography, and was assessed by left ventricular (LV) catheterisation at month 16 (prevention-study) or month 20 (therapy-study) as previously described.[18] After 8 months anti-β1EC2-positive untreated rats developed LV-dilatation and -dysfunction that progressed continuously in the course of both studies. In the prevention-study, echocardiography and cardiac catheterisation (Fig. 2C and D, and S2 Fig.: A, C, E and G) as well as histomorphology of the hearts (Table 1) of untreated vs. treated animals revealed that both bisoprolol and β1EC2-CP were able to prevent development of cardiomyopathy and heart failure. In the therapy-study, β1EC2-CP (injected either alone or as add-on to bisoprolol-treatment) almost fully reversed the cardiomyopathic phenotype that had developed before the initiation of therapy, whereas mono-therapy with bisoprolol only stopped further disease-progression. With β1EC2-CP (alone or as add-on), echocardiographic LV-dimensions, LV-ejection fraction and cardiac index (Fig. 2G), LV end-diastolic pressure and systolic contraction (Fig. 2H) as well as the heart weight of cardiomyopathic rats returned to control values (Table 2). In contrast, β1EC1-Lin or β1EC2-Lin failed to elicit any cardioprotective effects (S2 Fig.: B, D, and F). Unlike bisoprolol (alone or as add-on), neither linear peptides nor β1EC2-CP decreased heart rate or blood pressure of treated animals (S2 Fig.: G and H).

Morphometry and immunohistology of midventricular 2μm-sections of the hearts analysed at the end of the therapy-study underscored the beneficial effects of β1EC2-CP (alone or as add-on). The number of myocardial fibrotic scars (Fig. 3A and B) and TUNEL-positive apoptotic cells (Fig. 3C) returned to normal levels in β1EC2-CP-treated rats. Such a reversal was not seen with bisoprolol mono-therapy (Fig. 3A-C). By contrast, the increases in cardiac transcripts of distinct profibrotic markers (IL1-β, TGF-β1) observed in immunisation-
Table 1. Macroanatomy and haemodynamic parameters (prevention-study).

|                  | Control | Cont./biso. | Cont./EC2-CP | β1 immun. | β1 immun./biso. | β1 immun./EC2-CP |
|------------------|---------|-------------|--------------|-----------|-----------------|------------------|
| Heart, mg/g      | 2.55 ± 0.03 | 2.50 ± 0.06 | 2.50 ± 0.06 | 2.78 ± 0.04* | 2.55 ± 0.06 | 2.46 ± 0.05 |
| Spleen, mg/g     | 1.72 ± 0.15 | 1.79 ± 0.05 | 1.58 ± 0.15 | 1.63 ± 0.08 | 1.74 ± 0.05 | 1.48 ± 0.05 |
| Kidney R, mg/g   | 2.89 ± 0.07 | 2.90 ± 0.07 | 2.79 ± 0.01 | 2.78 ± 0.08 | 2.73 ± 0.07 | 2.79 ± 0.06 |
| Kidney L, mg/g   | 2.74 ± 0.10 | 2.79 ± 0.05 | 2.62 ± 0.08 | 2.68 ± 0.14 | 2.63 ± 0.04 | 2.71 ± 0.08 |
| Lung, mg/g       | 2.86 ± 0.09 | 2.66 ± 0.22 | 2.77 ± 0.10 | 2.89 ± 0.12 | 2.74 ± 0.07 | 2.74 ± 0.14 |
| Liver, mg/g      | 21.18 ± 0.98 | 22.33 ± 0.78 | 22.51 ± 0.20 | 24.71 ± 0.98† | 22.63 ± 0.46 | 23.59 ± 0.46 |
| Weight, g        | 580 ± 31  | 546 ± 8     | 553 ± 11     | 562 ± 4   | 533 ± 27        | 543 ± 24         |
| HF, bpm          | 246 ± 10  | 173 ± 17 †  | 232 ± 7      | 217 ± 4   | 178 ± 9 †       | 226 ± 5          |
| LVSP, mmHg       | 133 ± 6   | 107 ± 11*   | 135 ± 7      | 119 ± 1   | 106 ± 3 †       | 127 ± 4          |
| LVEDP, mmHg      | 9.9 ± 1.0 | 10.6 ± 1.5  | 10.1 ± 1.4   | 14.8 ± 0.4‡ | 8.3 ± 0.6       | 10.4 ± 0.6       |
| +dP/dt, mmHg/s   | 7667 ± 130| 7012 ± 419  | 7217 ± 83    | 6028 ± 23 ‡ | 6768 ± 106 †    | 7254 ± 118       |
| -dP/dt, mmHg/s   | 6021 ± 160| 5619 ± 155  | 5986 ± 288   | 5067 ± 76 ‡ | 5532 ± 78*      | 5887 ± 93        |

The upper part of the table shows the relative (wet) weights in g/kg body weight of selected organs in the groups of the prevention-study. Non-immunised 0.9% NaCl-injected rats had no intervention (Control) or received treatment with either bisoprolol (Cont./biso.) or β1-EC2-CP (Cont./EC2-CP). Similarly, immunised anti-β1-EC2-positive rats had either no intervention (β1-immun.) or received bisoprolol (β1-immun./biso.) or β1-EC2-CP (β1-immun./EC2-CP). Values given are mean weights ±SEM of heart, spleen, kidneys (R, right; L, left), lung, and liver, respectively. The lower part of the table shows invasively obtained haemodynamic parameters in the prevention-study. Parameters given are (from top to bottom, mean ±SEM): body weight (g), heart frequence (bpm), maximal systolic LV-pressure (mmHg), LV end-diastolic pressure (mmHg), contractilility (+dP/dt, mmHg/s), and relaxation (-dP/dt, -mmHg/s). One way ANOVA and Dunnett’s post-hoc test

Treated vs. control

*p < 0.05
†p < 0.01
‡p < 0.001.

doi:10.1371/journal.pone.0117589.t001

induced HF were reduced by ~ 50% with either β1-EC2-CP or bisoprolol mono-treatment, and even by >70% in the co-treatment group (indicating an synergistic anti-inflammatory effect, Fig. 3D). Also the documented increase in cardiac mast cells in immunized rats was reversed to control levels by both substances (either as mono- or as co-treatment, Fig. 3E). Further morphometric analysis of the hearts revealed enlarged LV-cavities and wall thinning in untreated cardiomyopathic rats. All these features, including the heart weight, were returned to normal in β1-EC2-CP-treated animals (Table 2 and Table 3). Moreover, the relative wet weight (Table 2), histology (S3 Fig.), and selected laboratory parameters (S4 Fig.) of other organs than the heart revealed an increase in lung and liver weight in untreated anti-β1-EC2-positive rats (accompanied by a significant increase in GLDH). These signs of congestion were almost reversed in β1-EC2-CP-treated, but not in bisoprolol mono-treated animals. Importantly, no β1-EC2-CP-related pathologies were noted in treated vs. control animals. In particular, neither the kidneys nor other inner organs, nor the eyes of β1-EC2-CP-treated rats had any signs of damage or organ-toxicity attributable to an accumulation or deposition of anti-β1EC2/β1EC2-CP-complexes (S3 Fig.).

Cardiac failure is usually accompanied by downregulation of cardiac β1- but not β2-ARs, and by upregulation of cardiac GRKs [4,23,24]. Radioligand-binding studies with [125I]-cyano-pindolol and selective antagonists showed that β1-specific downregulation of β-ARs also occurred in our immunisation-induced HF-model [18], and that this downregulation was largely prevented by (mono-)application of β1-EC2-CP alone (Fig. 4A and B). As typical for a β-AR antagonist, bisoprolol (mono-)treatment even induced a small increase in cardiac β1-ARs, an
Table 2. Macroanatomy and haemodynamic parameters (therapy-study).

|                     | Control | Cont./biso. | Cont./EC2-CP | β1 immun. | β1 immun./EC2-CP | β1 immun./EC2-Lin. | β1 immun. EC1-Lin. | β1 immun. EC2-CP+biso. |
|---------------------|---------|------------|--------------|-----------|-----------------|--------------------|-------------------|-----------------------|
| Heart, mg/g         | 2.10 ± 0.04 | 2.27 ± 0.09 | 2.15 ± 0.08  | 3.18 ± 0.22 | 2.93 ± 0.11†  | 2.20 ± 0.09        | 2.88 ± 0.24*       | 2.91 ± 0.12*          | 2.37 ± 0.08           |
| Spleen, mg/g        | 1.31 ± 0.08  | 1.54 ± 0.05  | 1.18 ± 0.03  | 1.50 ± 0.08 | 1.69 ± 0.07   | 1.23 ± 0.04        | 1.49 ± 0.09        | 1.27 ± 0.09           | 1.62 ± 0.07           |
| Kidney R, mg/g      | 2.34 ± 0.10  | 2.22 ± 0.09  | 2.47 ± 0.13  | 2.57 ± 0.10 | 2.25 ± 0.05   | 2.36 ± 0.20        | 2.23 ± 0.08        | 2.37 ± 0.07           |                     |
| Kidney L, mg/g      | 2.28 ± 0.07  | 2.19 ± 0.07  | 2.42 ± 0.12  | 2.54 ± 0.07 | 2.29 ± 0.06   | 2.32 ± 0.14        | 2.36 ± 0.07        | 2.27 ± 0.06           |                     |
| Lung, mg/g          | 2.16 ± 0.15  | 2.07 ± 0.06  | 2.96 ± 0.09† | 2.88 ± 0.10*| 2.26 ± 0.16   | 2.77 ± 0.12*       | 2.98 ± 0.09†       | 2.35 ± 0.08           |                     |
| Liver, mg/g         | 2.91 ± 0.70  | 18.5 ± 0.55  | 18.9 ± 0.55  | 22.95 ± 0.71†| 21.61 ± 1.47* | 19.83 ± 0.50       | 22.64 ± 0.59*      | 22.89 ± 0.41*         | 20.19 ± 0.66         |
| Weight, g           | 710 ± 26    | 613 ± 22†   | 695 ± 27     | 648 ± 22   | 598 ± 13       | 673 ± 12           | 598 ± 38           | 689 ± 21              | 606 ± 16             |
| HF, bpm             | 221 ± 3     | 168 ± 6†    | 221 ± 7      | 214 ± 4    | 173 ± 3†       | 217 ± 3            | 210 ± 6            | 217 ± 6              | 182 ± 2†             |
| LVSP, mmHg          | 125 ± 6     | 104 ± 4*    | 121 ± 8      | 108 ± 3*   | 126 ± 4        | 116 ± 4            | 114 ± 6            | 104 ± 3*             | 108 ± 3*             |
| LVEDP, mmHg         | 7.8 ± 0.8   | 9.7 ± 0.9   | 9.2 ± 1.1    | 10.8 ± 0.8†| 10.9 ± 1.3     | 10.0 ± 1.0         | 14.5 ± 1.2*        | 13.8 ± 0.6*           | 10.0 ± 0.6           |
| +dP/dt, mmHg/s      | 6979 ± 173  | 6018 ± 308  | 6566 ± 416   | 5249 ± 225†| 5697 ± 231†    | 6559 ± 190         | 5902 ± 171*        | 5146 ± 384‡           | 6238 ± 193           |
| -dP/dt, mmHg/s      | 5765 ± 309  | 4646 ± 295† | 5502 ± 248   | 4079 ± 159†| 4238 ± 117†    | 5228 ± 166         | 4857 ± 157*        | 3996 ± 106‡           | 4991 ± 106            |

The upper part of the table shows the relative (wet) weights in g/kg body weight of selected organs in the groups of the therapy-study. Non-immunised 0.9% NaCl-injected rats had no intervention (Control) or received treatment with either bisoprolol (Cont./biso.) or β1EC2-CP i.v. (Cont./EC2-CP). Similarly, immunised anti-β1EC2-positive rats remained either untreated (β1-immun.) or were treated with (oral) bisoprolol (β1-immun./biso.) or i.v.-injected with β1EC2-CP, β1EC2-Lin, or β1EC1-Lin (β1-immun./EC2-CP/EC2-Lin/EC1-Lin), or received β1EC2-CP/bisoprolol co-treatment (β1-immun./EC2-CP+biso.). Values given are mean weights ±SEM of heart, spleen, kidneys (R, right; L, left), lung, and liver, respectively. The lower part of the table shows invasively obtained haemodynamic parameters in the therapy-study. Parameters given are (from top to bottom, mean ±SEM): body weight (g), heart frequency (bpm), maximal systolic LV-pressure (mmHg), LV end-diastolic pressure (mmHg), contractility (+dP/dt, mmHg/s), and relaxation (-dP/dt, -mmHg/s). One way ANOVA and Dunnett’s post-hoc test

Treated vs. control
*p<0.05
†p<0.01
‡p<0.001.

doi:10.1371/journal.pone.0117589.t002

The effect that was fully preserved with β1EC2-CP/bisoprolol co-treatment (Fig. 4B). No changes were seen for β2-AR under any of the study conditions. Corresponding to the downregulation of cardiac β1-AR protein, β1-AR mRNA-levels were also significantly reduced in untreated cardiomyopathic rats and returned to normal levels with either β1EC2-CP or bisoprolol treatment alone or with β1EC2-CP/bisoprolol combination-therapy (Fig. 4C). Moreover, qPCR-analysis of the expression of G protein-coupled receptor kinases (GRKs) involved in counter-balancing sympathetic activity [4,24,25] revealed an upregulation of GRK2 and GRK5 in immunisation-induced HF, which was reverted by both β1EC2-CP and (to a somewhat lesser extent) by bisoprolol mono-therapy (Fig. 4C), whereas co-treatment with both substances had a clear synergistic effect, resulting even in a slight (non-significant) down-regulation of both GRK’s (Fig. 4C).
Immunomodulating effects of β₁-EC2-cyclopeptides

To assess whether preventive and/or therapeutic treatment of anti-β₁EC2-positive rats with the different peptides interfered with the immunopathology of antibody-induced HF, we determined the kinetics of anti-β₁EC2-antibodies before and 24 h after peptide-application by ELISA (measuring only free anti-β₁EC2-antibodies). In immunised untreated animals, anti-β₁EC2-titers continuously increased after each antigen-boost (Fig. 2B and F). In line with an antibody-scavenging effect, treatment with β₁EC2-CP already after two injections significantly decreased, and after 5 injections almost fully suppressed a rise in free anti-β₁EC2, while bisoprolol...
Table 3. Morphometric analysis of rat hearts (therapy-study).

|                  | Control | Cont./ biso. | Cont./EC2-CP | β1 immun. /biso. | β1 immun. /EC2-CP | β1 immun. /EC2-Lin. | β1 immun. EC1-Lin. | β1 immun. EC2-CP + biso. |
|------------------|---------|--------------|--------------|------------------|------------------|---------------------|---------------------|--------------------------|
| LVA, mm²        | 59.9 ±1.8 | 58.4 ±0.7    | 57.4 ±0.7    | 68.3 ±0.8*      | 61.9 ±5.2       | 65.2 ±2.5           | 71.2 ±3.5†          | 70.9 ±1.4*               | 55.4 ±1.7               |
| LVCA, mm²       | 24.1 ±0.9 | 22.6 ±0.2    | 21.3 ±0.1    | 31.1 ±0.3‡      | 26.8 ±1.0       | 25.6 ±1.0           | 32.7 ±1.3‡          | 32.4 ±1.5‡              | 22.5 ±1.5               |
| LVWA, mm²       | 36.9 ±1.3 | 35.8 ±0.5    | 36.1 ±0.7    | 37.2 ±0.7       | 35.0 ±4.5       | 39.6 ±1.7           | 38.5 ±2.4           | 38.5 ±0.8               | 34.8 ±1.6               |
| LVCA / LVA %    | 39.6 ±0.8 | 38.7 ±0.5    | 37.2 ±0.5    | 45.6 ±0.8‡      | 43.9 ±0.8       | 46.1 ±0.9‡          | 45.6 ±1.4‡          | 37.1 ±1.2               |                         |
| IVS, mm         | 1.7 ±0.1  | 1.8 ±0.1     | 1.7 ±0.1     | 1.5 ±0.1*       | 1.7 ±0.1        | 1.7 ±0.1            | 1.5 ±0.1*           | 1.4 ±0.1                | 1.6 ±0.2                |
| PW, mm          | 1.8 ±0.1  | 1.8 ±0.1     | 1.9 ±0.1     | 1.6 ±0.1*       | 1.5 ±0.1        | 1.8 ±0.1            | 1.6 ±0.1*           | 1.6 ±0.1                | 1.7 ±0.1                |

Morphometric data of rat hearts harvested at the end of the therapy-study were obtained by computer-aided analysis of H&E-stained mid-ventricular 2 μm cross-sections as previously described in detail [18]. Parameters given are (from top to bottom, mean ±SEM): LVAtot, total LV-area; LVCA, LV-cavity area; LVWA, LV wall area (including LVCA/LVWA-ratio in %); IVS, thickness of the inter-ventricular septum; PW, posterior wall thickness (one way ANOVA and Dunnett’s post-hoc test).

Treated vs. control
*p<0.05
†p<0.01
‡p<0.001.

doi:10.1371/journal.pone.0117589.t003

Treatment did not affect the amount of free anti-β1EC2-αbs. With preventive and also with (repeated) therapeutic application of β1EC2-CP, anti-β1EC2-levels remained low despite continued boosting with β1EC2/GST-FPs (Fig. 2B and F). This unexpected titer-course, monitored more closely in the first 6 months of the prevention-study (Fig. 5A), suggested that beside its function as a simple scavenger, β1EC2-CP also negatively impacted on B- and/or T-cells as the lymphocyte populations responsible for anti-β1EC2-production. Moreover, as even preventive injection was initiated after the priming-immunisation and production of class-switched anti-β1EC2 of the IgG isotype, β1EC2-CP-treatment putatively interfered with the function not of naïve, but of already differentiated memory B-cells, plasma cells (PC), and/or T-cells.

For T-cells, treatment with antigenic peptides has been shown to either induce dominant unresponsiveness of the CD4⁺ T cell-compartment via induction of CD4⁺CD25⁺ regulatory T-cells (Treg cells) [26] or to functionally impair non-Treg CD4⁺ T helper cells [27]. We, therefore, tested the in vitro recall responses of purified CD4⁺ T-cells isolated from the spleens of preventively (Fig. 5B and C) or therapeutically (Fig. 5D) treated and untreated rats to the β1EC2/GST-FP and its components. CD4⁺ T-cells from both groups clearly responded to the FP but not to β1EC2-CP, indicating that the relevant CD4⁺ T-cell epitopeces were contained within GST (Fig. 5B-D). Further in vitro testing did also not provide any evidence for an induction of β1EC2-specific Treg cells by β1EC2-CP in vivo (not shown).

As the T cell-compartment appeared not to be targeted by β1EC2-CP we further analysed the cells directly involved in antibody-production, i.e. B-cells and PC. ELISPOT assays using splenocytes or bone marrow cells freshly isolated from rats two weeks after the last antigen-boost allowed us to determine the frequencies of (mostly) long-lived PC in these organs; however, these experiments revealed that β1EC2-CP-treatment did not reduce the frequencies of anti-β1EC2-producing PC (Fig. 5E and F).

While long-lived PC express very little or no immunoglobulins on the cell surface [28], B-cells do and could thus serve as direct targets of β1EC2-CPs. To detect the few antigen-
specific memory B-cells within splenocytes of treated vs. untreated rats we differentiated memory B-cells into short-lived plasmablasts by boosting the rats with β1EC2/GST-FPs three days prior to the analysis [29]. This allowed us to detect them together with long-lived PC by ELISPOT.

Preventive (Fig. 5G and H) as well as therapeutic (Fig. 5I and J) application of β1EC2-CPs resulted in a ~80% reduction in the frequencies of splenocytes secreting anti-β1EC2-abs, which was not achieved with β1EC2-Lin (S5A Fig.). As long-lived PC were not targeted by β1EC2-CPs (Fig. 5E), this means that more than 80% of the β1EC2-specific memory B-cells were affected by this kind of treatment impairing B-cell receptor (BCR)-mediated β1EC2-specific memory B-cell expansion and differentiation into anti-β1EC2-producing PC. Direct detection of β1EC2-specific memory B-cells by flow cytometry (Fig. 5K and L) further revealed complete depletion of this cell population by β1EC2-CP treatment. Accordingly, transfer of purified B-cells from immunised β1EC2-treated rats into antigen-naïve recipients followed by suboptimal immunisation with β1EC2/GST-FP (12.5μg instead of 50μg in
adjuvans) did not induce detectable amounts of anti-β1EC2-β1EC2-ab in the serum of the recipient rats while B-cells from immunised untreated rats did (Fig. 5F). In summary, our results suggest that β1EC2-CP protects rats from immunisation-induced HF, both, by specifically scavenging free anti-β1EC2 and by depleting β1EC2-specific memory B-cells. It should be noted, however, that the overall numbers of IgG-producing cells were not at all affected by β1EC2-CP-treatment (Fig. 5F, H, and J), precluding a general immuno-suppressant effect of the cyclic peptide.

Discussion

Autoantibody-induced diseases and current treatment approaches

Autoantibodies directed against self-antigens are the hallmark of many autoimmune diseases, and some of them may even directly cause the disease [30,31]. In Graves’ disease [32], myasthenia gravis [33], and a sub-entity of insulin-resistant diabetes [30] functional autoantibodies (abs) directed against membrane receptors have been recognised as main pathogenetic factors. This illustrates that receptors, proteins that are generally considered as not very immunogenic, can serve as targets for disease-causing abs. This appears to be the case also in a significant number of HF patients, where anti-β1AR-abs are suspected to contribute to the development of DCM [2,6,7,8,10,11,18,34,35,36].

Current treatment approaches in autoantibody-induced diseases comprise either targeting the abs themselves, as is the case for immunoabsorption [36], or the cells producing the abs, i.e. short-lived plasmablasts and/or long-lived plasma cells. While plasmablasts and their precursors, i.e. memory B-cells, may be deleted by cytostatic drugs like cyclophosphamide [37] or anti-CD20-α-abs [38], ablation of long-lived plasma cells requires the use of proteasome-inhibitors [39]. All these therapies present specific problems in terms of unwanted effects and outcome; in particular, proteasome-inhibitors are quite cardiotoxic, rendering them not suitable for the treatment of anti-β1AR-mediated HF [40].

Here we present a novel approach to address such disease-causing abs based on cyclic peptides mimicking the relevant target-epitope. We and others have previously shown that immunisation against the 2nd extracellular loop of the β1AR gives rise to receptor-stimulating anti-β1EC2 in various animal models [12,14,18,35,41]. Such antibodies appear to allosterically activate the receptors and their signaling cascade, and this activation occurs both in the absence and in the presence of catecholamines [6,12,18]. In the long run, such anti-β1EC2 cause myocardial tissue injury, characterised by myocyte apoptosis and fibrosis, myocyte dysfunction, cardiac dilatation, and in the end congestive HF [5,6]. The most likely explanation is that
stimulating anti-β1EC2 abs cause partial, but chronic activation of cardiomyocyte β1-ARs, and thus potentiate the vicious circle of sympathetic activation and HF-progression [3,4,6].

Mode of action of β1-receptor mimicking cyclic peptides

In our study, monthly injections of β1EC2-CP either prevented (preventive application) or even reversed (therapeutic application) the detrimental consequences of stimulating anti-β1EC2. These injections were tolerated well by both immunised anti-β1EC2-positive rats and antibody-naïve control animals, and over one year of treatment did not elicit any apparent β1EC2-CP-related adverse effects, neither in routine blood laboratory tests nor in a series of organs (S3 and S4 Figs.). In addition, the protection achieved with monthly β1EC2-CP-injections was clearly superior to daily applications of 15 mg/kg bisoprolol alone, although mono-treatment with bisoprolol was able to stop the progression of immunisation-induced heart failure. Unlike bisoprolol, β1EC2-CP mono-treatment affected neither heart rate nor blood pressure. The beneficial effects of β1EC2-CP must at least in part be due to scavenging of anti-β1EC2, as is evident from the specific and high-affinity recognition of these antibodies which reflects both the primary sequence of the epitope (by comparison with the β1EC1- or β2EC2-peptides) as well as the structure (by comparison with the linear β1EC2-peptide). In addition, β1EC2-CP had a long half-life in blood, which contributes to its scavenging-efficacy.

In addition to its anti-β1EC2-neutralizing action, the most intriguing effect of β1EC2-CP was the ability to essentially block further anti-β1EC2 antibody-production despite continuous antigen-boosts. As detailed in the results-section this failure to respond to the antigen boosts is due to depletion or functional inactivation of β1EC2-specific memory B-cells. On a molecular level this depletion is explained by monomeric, e.g. non-productive, stimulation of the BCR [42] precluding an expansion of anti-β1EC2-expressing memory B-cells in β1EC2-CP-treated animals.

As in the case of direct scavenging, the effect on anti-β1EC2-expressing memory B-cells was sequence- and epitope-specific, and was, in particular, not elicited by the corresponding linear peptide (S2 and S5 Figs.).

While direct targeting of PC in anti-β1EC2-mediated HF remains a challenge, the cyclopeptide-approach presented here neutralises the products of short-lived plasmablasts as well as long-lived PC (i.e. existing anti-β1EC2-antibodies) and hits β1EC2-specific memory B-cells. Although antibody-neutralisation appears sufficient to mediate protection in this model, we hypothesise that depletion of the β1EC2-specific memory B-cells may be important for maintaining low antibody-titers and, therefore, enhances the long-term therapeutic efficacy of our approach. By this double action β1EC2-CPs not only prevent antibody-induced β1-AR activation, but also address the site of antibody-generation, and thereby prevent or revert anti-β1EC2-induced cardiac damage. These positive effects were seen in terms of cardiac morphology and function as well as different microscopic, laboratory, and molecular parameters. Moreover, in β1EC2-CP-treated animals, together with the restauration of cardiac membrane β1-AR, also the increases in GRK2- and GRK5-expression were almost fully reverted. These effects were even more pronounced, when injecting β1EC2-CP (as an add-on) to bisoprolol-treatment, resulting in a slight (non-significant) downregulation of both GRK’s. This is of particular interest, as increases in cardiac GRK-transcripts are thought to represent an early adaptation to adrenergic stress preceding β1-AR desensitisation [4,43,44]. In addition, increases in cardiac GRK-transcripts have been shown to correlate well with disease severity in HF patients [44], suggesting that β1EC2-CP treatment alone or—on a molecular level even more efficient—combined with a β1-receptor blocking agent (which corresponds better to the current clinical
requirements and treatment guidelines) might also act beneficially in anti-β₁EC2-mediated human heart failure.

**Chronic heart failure, relevance of the immune system, and new therapeutic strategies**

Various factors may contribute to non-ischaemic DCM, including persistent viral infection [45] and autoimmune-mediated damage to myocytes [46,47,48]. These factors may coincide, because autoimmune-reactions to myocardial proteins may be virus-triggered [31,47]. In the last decade a growing number of heart-directed abs and alterations of the immune system have been described in heterogeneous subsets of patients with DCM [34,46,49], indicating that multiple mechanisms may play a role in the pathogenesis of autoimmune-mediated heart failure (HF). Amongst others, abnormalities have been found in cytokines [46], T lymphocyte subsets, and in cells mediating myocardial inflammation [50]. Moreover, in >30% of DCM patients abnormal immune-reactions against distinct cardiac self-antigens have been described, including autoantibodies against myocyte contractile proteins [47,51], mitochondrial proteins [52], and membrane receptors [10,53,54]. However, only a few of them have been shown to cause, in fact, myocardial tissue injury and congestive HF by themselves [18,35,51]. In humans the individual genetic predisposition also significantly influences the susceptibility to self-directed immune-reactions [34,49,55], but the so far available clinical data underscore the pathophysiological and clinical importance of stimulating anti-β₁AR-abs in HF and the need for novel antibody-directed therapeutic strategies [6,36,56]. We demonstrate here that anti-β₁EC2-mediated cardiostimulatory effects in vivo cannot be efficiently neutralised with β₁-receptor blockers alone. This finding fits perfectly with in vitro data using anti-β₁EC2 isolated from DCM-patients [8]. Other experimental antibody-directed strategies consist in their removal from the blood by immunoadsorption [36,57,58] or, more recently, in the development of anti-β₁AR-neutralising small oligonucleotides currently assayed in vitro [56].

As a simple alternative, we present here a novel specific and very efficient strategy to treat autoimmune-mediated HF in vivo with cyclopeptides mimicking the target-domain of stimulating anti-β₁EC2-antibodies (administered alone or as an add-on to β₁-receptor blocker treatment). β₁EC2-CPs acted as antibody-scavengers in the circulation thereby precluding antibody-induced harm from the heart; in addition, the cyclic peptides were found to have a long-term effect by selectively depleting memory B-cells involved in antibody-production. Our data suggest that β₁EC2-CPs (alone or combined with a β₁-receptor blocking drug) might evolve into a novel save and efficient strategy to neutralise stimulating anti-β₁EC2 also in human HF. Furthermore, it will be interesting to investigate whether such cyclic peptides might prove to be beneficial also in other autoantibody-mediated diseases.

**Conclusions**

By taking advantage of a human-analogous rat model the here presented in vivo-experiments provide the basis for the clinical translation of a novel double-acting therapeutic strategy for immune-mediated heart failure. Cyclic peptides mimicking the target epitope of functionally active antibodies stimulating the cardiac β₁-adrenergic receptor on the one hand act as direct antibody-scavengers in the circulation thereby precluding antibody-induced harm from the heart; in addition, the cyclic peptides were found to have a long-term effect by selectively depleting memory B-cells involved in the production of cardio-noxious receptor antibodies. Besides the prevention and/or treatment of immune heart failure (either as a mono-substance or combined with a β₁-receptor blocking agent) the here presented approach might be helpful also in other autoantibody-mediated diseases.
Supporting Information

S1 Fig. Effect of different peptides on anti-β1EC2-antibody titres (therapy-study). Time course of anti-β1EC2-titers in the therapy study measured before and 24h after CP-injections. Absolute antibody-concentrations over 20 study-months are shown (mg/ml; black circles, untreated; green diamonds: β1EC2-CP (1.0 mg/kg/month i.v.); blue triangles: bisoprolol (15 mg/kg/day orally); grey squares: β1EC2-Lin (1.0 mg/kg/month i.v.); green squares: β1EC1-Lin (1.0 mg/kg/month i.v.)); for better readability error-bars are not shown in the graph.

S2 Fig. Effect of different peptides on various echocardiographic and haemodynamic parameters in the prevention- and the therapy-study. Echocardiographic follow-up in the (A, C) prevention- and (B, D) therapy-study. Graphs (A) and (B) show the time-course of LV end-diastolic and end-systolic diameters (LVED, LVES), graphs (C) and (D) the cardiac index (derived from cardiac output/body weight) in the prevention- and the therapy-arm of the study, respectively. Error bars indicate mean ±SEM; */p < 0.01, **p < 0.001, ***p < 0.0001 (two way ANOVA and Bonferroni post-hoc test). Invasively obtained haemodynamic parameters in the (E) prevention- and (F) therapy-study. Panels (from top to bottom) show heart frequency (bpm), maximal systolic LV-pressure (mmHg), LV end-diastolic pressure (mmHg), LV-contracility (+dP/dt, mmHg/s), and -relaxation (-dP/dt, -mmHg/s). Error bars indicate mean ±SEM; */p < 0.01; **p < 0.001, ***p < 0.0001 (one way ANOVA and Dunnett’s post-hoc test).

S3 Fig. Histologic analysis of various organs (therapy-study, mono-treatment). Representative H&E-stained 2μm cross-sections from various organs analyzed for treatment-related pathologies. Panels (from top to bottom) show organs analyzed from immunised anti-β1EC2-positive untreated, β1EC2-CP-treated, or bisoprolol-treated rats. Representative sections from brain, liver, heart, kidney, eye, and spleen after 12 months of treatment are demonstrated. Neither treatment strategy caused detectable organ-specific toxicity or therapy-related pathologies.

S4 Fig. Routine laboratory parameters (therapy-study, mono-treatment). Columns ± error bars represent the mean values ±SEM for different laboratory serum parameters in the indicated treatment groups (from left to right, top row: AST, aspartate-aminotransferase; ALT, alanine-aminotransferase; aP, alkaline phosphatase; Crea, creatinine; Urea, urea. Bottom row: GGT, gamma-glutamyltransferase; GLDH, glutamat lactate dehydrogenase; Bili, bilirubin; Myo, myoglobin; CK, creatinine kinase); */p < 0.05 (one way ANOVA and Dunnett’s post-hoc test).

S5 Fig. Effect of cyclic versus linear peptides on splenocytes. ELISPOT-assays carried out with bone marrow cells (BM) and splenocytes prepared from immunised untreated (black, n = 3) vs. β1EC2-CP-treated (dark green, n = 5) vs. β1EC2-Lin-treated animals (light green, n = 3). Columns in (A) depict the fraction of anti-β1EC2-secreting cells 3 days after antigen-boost (in % of IgG-producing cells); columns in (B) show the total amount of IgG-producing cells per 10⁶cells. Error bars indicate mean ±SEM; */p < 0.05 (one way ANOVA and Dunnett’s post-hoc test).

Acknowledgments

We are deeply indebted to Sandra Werner and Christina Zechmeister for excellent technical assistance. Bisoprolol was kindly donated from BAYER Health Care Inc., Düsseldorf, Germany.
Author Contributions
Conceived and designed the experiments: VB NB DP VON AS TK GE MJL RJ. Performed the experiments: VB NB DP VON AS JM DS VK RJ. Analyzed the data: VB NB DP VON AS JM DS VK TK TH GE MJL RJ. Contributed reagents/materials/analysis tools: NB DP VON AS JM TK TH MJL. Wrote the paper: VB NB VON AS JM VK TK TH GE MJL RJ.

References
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388–2442. doi: 10.1093/eurheartj/ehn309 PMID: 18799522
2. Störk S, Boivin V, Horf R, Hein L, Lohse MJ, et al. (2006) Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 152: 697–704. PMID: 16996841
3. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823. PMID: 6382011
4. Bristow MR (2011) Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 109: 1176–1194. doi: 10.1161/CIRCRESAHA.111.245092 PMID: 22034480
5. Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93: 896–906. PMID: 14615493
6. Freedman NJ, Lefkowitz RJ (2004) Anti-beta1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 113: 1379–1382. PMID: 15146232
7. Hébert TE (2007) Anti-beta1-AR antibodies in dilated cardiomyopathy: are these a new class of receptor agonists? Cardiovasc Res 76: 5–7. PMID: 17707357
8. Nikolaev VO, Boivin V, Stork S, Angermann CE, Ertl G, et al. (2007) A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. Journal of the American College of Cardiology 50: 423–431. PMID: 17662395
9. Maron BJ, Towbin JA, Thieme G, Antzelevitch C, Corrado D, et al. (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807–1816. PMID: 16567565
10. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, et al. (1999) Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99: 649–654. PMID: 9950682
11. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, et al. (2001) Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 37: 418–424. PMID: 11216956
12. Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, et al. (2000) Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol 36: 1280–1287. PMID: 11028484
13. Warne T, Serrano-Vega MJ, Baker JG, Moukharetzianov R, Edwards PC, et al. (2008) Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454: 486–491. doi: 10.1038/nature07101 PMID: 18594507
14. Maghrison Y, Hoyer S, Lengagne R, Chapot MP, Guillet JG, et al. (1989) Antigenic analysis of the second extracellular loop of the human beta-adrenergic receptors. Clin Exp Immunol 78: 42–48. PMID: 2478327
15. Hoebeke J (1996) Structural basis of autoimmunity against G protein-coupled membrane receptors. Int J Cardiol 54: 103–111. PMID: 8803673
16. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. (2007) High resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258–1265. PMID: 17962520
17. Bomholz B, Weidtkamp-Peters S, Schmitteier S, Seidel CAM, Herda LR, et al. (2013) Impact of human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res: 472–480. doi: 10.1093/cvr/cvt206 PMID: 23975852

18. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, et al. (2004) Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113: 1419–1429. PMID: 15146239

19. Ireland DC, Colgrave ML, Nguyencong P, Daly NL, Craik DJ (2006) Discovery and characterization of a linear cyclotide from Viola odorata: implications for the processing of circular proteins. J Mol Biol 357: 1522–1535. PMID: 16488428

20. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, et al. (1987) Cloning of the cDNA for the human beta1-adrenergic receptor. Proc Natl Acad Sci USA 84: 7920–7924. PMID: 2825170

21. Jahns R, Siegmund C, Jahns V, Reiländer H, Maidhof A, et al. (1996) Probing human beta1- and beta2-adrenoceptors with domain-specific fusion protein antibodies. Eur J Pharmacol 316: 111–121. PMID: 8982658

22. Litwin SE, Katz SE, Morgan JP, Douglas PS (1994) Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 89: 345–354. PMID: 8281668

23. Bristow MR (1993) Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 22: 61A–71A. PMID: 8397233

24. Ungerer M, Parruti G, Böhm M, Puzicha M, De BA, et al. (1994) Expression of b-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res 74: 206–213. PMID: 8293560

25. Martini JS, Raake P, Vinge LE, DeGeorge BR Jr., Chuprun JK, et al. (2008) Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A 105: 12457–12462. doi: 10.1073/pnas.0803153105 PMID: 18711143

26. Thorstenson KM, Khoruts A (2001) Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 167: 188–195. PMID: 11418648

27. Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162: 5775–5783. PMID: 10229810

28. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A (1998) Survival of long-lived plasma cells is independent of antigen. Int Immunol 10: 1703–1711. PMID: 9846699

29. Savelyeva N, King CA, Vitetta ES, Stevenson FK (2005) Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help. Proc Natl Acad Sci U S A 102: 10987–10992. PMID: 16037207

30. Naparstek Y, Plotz PH (1993) The role of autoantibodies in autoimmune disease. Annu Rev Immunol 11: 79–104. PMID: 8476578

31. Rose NR (2001) Infection, mimics, and autoimmune disease. J Clin Invest 107: 943–944. PMID: 11306595

32. Endo K, Kasagi K, Konishi J, Ikekubo K, Okonu T, et al. (1978) Detection and properties of TSH-binding inhibitory immunoglobulins in patients with Grave’s disease and Hashimoto’s thyroiditis. J Endocrinol Metab 46: 734–739. PMID: 45421

33. Tzartos SJ, Seybold ME, Lindstrom JM (1982) Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 79: 178–192.

34. Limas CJ, Iakovis P, Anyfantakis A, Kroupis C, Kokkinos DV (2004) Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 93: 1189–1191. PMID: 15110223

35. Jane-wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, et al. (2007) Beta1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 116: 1–12. PMID: 16924626

36. Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoabsorption. Ann NY Acad Sci 1051: 635–646. PMID: 16127004

37. Hoyer PF, Vester U (2004) The impact of cyclosporine on the development of immunosuppressive therapy—pediatric transplantation using cyclosporine. Transplant Proc 36: 1975–202S. PMID: 15041336

38. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6: 394–403. PMID: 16622478
39. Neubert K, Meister S, Moser K, Weisel F, Maseda D, et al. (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748–755. doi: 10.1038/nm1763 PMID: 18542049

40. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, et al. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138: 396–397. PMID: 17561972

41. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, et al. (2001) Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 88: 578–586. PMID: 11282891

42. Kim YM, Pan JY, Korbel GA, Peperzak V, Boes M, et al. (2006) Monovalent ligation of the B cell receptor induces receptor activation but fails to promote antigen presentation. Proc Natl Acad Sci U S A 103: 3327–3332. PMID: 16492756

43. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of β-adrenergic receptor and β1-adrenergic receptors in the failing human heart. Circulation 87: 454–463. PMID: 8381058

44. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, et al. (2006) Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovascular Research 69: 46–56. PMID: 16288730

45. Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, et al. (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112: 1965–1970. PMID: 16172268

46. Luppi P, Rudert WA, Zanone MM, Stassi G, Trucco G, et al. (1998) Idiopathic dilated cardiomyopathy. A superantigen-driven autoimmune disease. Circulation 98: 777–785. PMID: 9727548

47. Caforio AL, Mahon NJ, Tona F, McKenna WJ (2002) Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 4: 411–417. PMID: 12167378

48. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, et al. (2003) Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9: 1484–1490. PMID: 14625544

49. Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, et al. (2007) Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 115: 76–83. PMID: 17179019

50. Noutsias M, Rohde M, Goldner K, Block A, Blunert K, et al. (2011) Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Fail 13: 611–618. doi: 10.1093/eurjhf/hfr014 PMID: 21422001

51. Göser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, et al. (2006) Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114: 1693–1702. PMID: 17015788

52. Schulze K, Becker BF, Schauer R, Schultheiss HP (1990) Antibodies to ADP-ATP carrier—an autoantigen in myocarditis and dilated cardiomyopathy—impair cardiac function. Circulation 81: 959–969. PMID: 2155073

53. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J (1994) Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 89: 2760–2767. PMID: 8205690

54. Fu LXM, Magnusson Y, Bergh CH, Waagstein F, Hjalmarson Å, et al. (1993) Localization of a functional autoimmune epitope on the second extracellular loop of the human muscarinic acetylcholine receptor 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91: 1964–1968. PMID: 7683693

55. MacLellan WR, Lusis AJ (2003) Dilated cardiomyopathy: learning to live with yourself. Nat Med 9: 1455–1456. PMID: 14647516

56. Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I (2011) Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 109: 986–992. doi: 10.1161/CIRCRESAHA.111.253849 PMID: 21868696

57. Wallukat G, Müller J, Hetzer R (2002) Specific removal of beta1-adrenergic antibodies directed against cardiac proteins from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347: 1806. PMID: 12458665

58. Staudt A, Hummel A, Ruppert J, Dörr M, Trimpert C, et al. (2006) Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 152: 712e711–712e716. PMID: 16996843
59. Kaiser E, Colescott RL, Bossinger CD, Cook PI (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 34: 595–598. PMID: 5443684

60. Schmidt J, Elfein K, Stienekemeier M, Rodríguez-Palmero M, Schneider C, et al. (2003) Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 140: 143–152. PMID: 12864982